Given that HK2 plays the crucial role for cell growth in Kras overexpression and p53 function lose-driven lung cancer cells in vitro and in vivo, pharmacologically targeting HK2 may be explored as an effective therapy for NSCLC. The gene discussed is HK2; the disease is lung carcinoma.